David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2

July 01, 2020

In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.

High Hopes for Inclisiran. Will the Third Time be the Charm for PCSK9 Inhibition?

June 22, 2020

The two PCSK9 inhibitors have fallen far short of expectations. Inclisiran, which works by RNA inference, only needs to be injected twice a year. 

4 Ways PBMs are Changing

June 22, 2020

Pharmacy benefit managers are taking steps to be more responsible for the total cost of care and to become more transparent, while adding technology tools to support patients, payers and physicians in a post-COVID-19 world.

The Pharmaceutical Industry’s Role in a COVID-19 Vaccine

June 11, 2020

Drug makers around the world are racing to develop the first effective COVID-19 vaccine. Early efforts show promise, but an anticipated jump in the novel coronavirus cases in the fall means the sooner a vaccine is developed, the more lives can be saved-and the pharmaceutical industry plays a major role in this discovery.

Siponimod Enters Crowded Market of DMTs for SPMS

June 04, 2020

The Institute for Clinical and Economic Review (ICER) found siponimod has benefits for patients with active secondary progressive multiple sclerosis, but its benefits were in line with other therapies in a crowded marketplace.

AstraZeneca’s Tagrisso Keeps Most Lung Cancer Patients With Mutation Alive Two Years After Surgery

June 01, 2020

Tagrisso, the targeted therapy made by AstraZeneca, could become the treatment of choice for the majority of lung cancer patients with mutations in a certain gene who are treated after surgery, based on findings presented this past weekend at the American Society of Clinical Oncology annual meeting.

Martin VanTrieste Leads the Way at Civica Rx

May 21, 2020

He was reluctant to take the CEO job, but VanTrieste has the unique nonprofit drug manufacturer surpassing its goals and possibly branching out into the retail market.

Claim Analysis By Specialty Pharmacist Saves Health Plan $2.7 Million, Study Finds

May 20, 2020

A new study highlights the role a qualified specialty pharmacist can play in driving down costs across a health plan.

Adherence to Disease-Modifying Drugs Lowers Chronic Opioid Use in Patients with Inflammatory Conditions

May 19, 2020

A study of patients with inflammatory conditions who were prescribed biologic disease-modifying anti-rheumatic drugs had lower rates of chronic opioid use if they were adherent to their biologic therapy, according to new research.